Welcome to our dedicated page for MoonLake Immunotherapeutics news (Ticker: MLTX), a resource for investors and traders seeking the latest updates and insights on MoonLake Immunotherapeutics stock.
MoonLake Immunotherapeutics reports clinical, regulatory and financing developments for a clinical-stage biotechnology business focused on inflammatory skin and joint diseases. Its updates center on sonelokimab (SLK), a Nanobody designed to inhibit IL-17A and IL-17F, and on programs in hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis and palmoplantar pustulosis.
Recurring news includes Phase 2 and Phase 3 trial data from VELA, VELA-TEEN, MIRA, LEDA, S-OLARIS and IZAR studies, FDA interactions and designations tied to SLK, quarterly financial results, research and development spending, equity and debt financing activity, and shareholder voting or capital-structure matters.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
ZUG, Switzerland, April 19, 2023 – MoonLake Immunotherapeutics AG (Nasdaq: MLTX) is hosting its Capital Markets Day in New York, featuring a live webcast for virtual attendees. The event runs from 10:30-12:30 EDT and includes presentations from the executive team discussing a financial update, near-term catalysts, and the company’s publication roadmap.
The focus will be on sonelokimab, a novel investigational Nanobody® targeting inflammatory diseases, along with an update from Professor Kenneth B. Gordon on treatment landscapes following the AAD Annual Meeting. Top-line results for sonelokimab’s Phase 2 trial in hidradenitis suppurativa are anticipated by June 2023, with additional trials in psoriatic arthritis ongoing.
MoonLake Immunotherapeutics (NASDAQ:MLTX) reported its Q4 and year-end financial results for 2022, revealing a strong cash position of $72.1 million, providing operational runway into 2H 2024.
The company has completed patient enrollment ahead of schedule in its global Phase 2 trial of sonelokimab for Hidradenitis Suppurativa, with top-line results expected by June 2023. Additionally, enrollment for the Psoriatic Arthritis trial is ongoing and on schedule, with results anticipated by year-end. The net loss for the year was $64.5 million, an increase from $53.6 million in the prior period. The CEO highlighted the successful initiation of clinical trials and competitive positioning in the IL-17 inhibitor market.